# Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults

> **NCT02367638** · PHASE1 · COMPLETED · sponsor: **Green Cross Corporation** · enrollment: 39 (estimated)

## Conditions studied

- Varicella (Chicken Pox)

## Interventions

- **BIOLOGICAL:** MG1111
- **BIOLOGICAL:** VARIVAX

## Key facts

- **NCT ID:** NCT02367638
- **Lead sponsor:** Green Cross Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2015-07
- **Final completion:** —
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2017-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02367638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02367638, "Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02367638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*